Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.43 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.43 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HRAS | P01112 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695833 | 0.98 | NPC1 (0.53) | NPC1RAB9ATSHRAGXTIDO1 | |
| Fluoride SCHEMBL27626551 | 0.95 | NPC1 (0.52) | NPC1RAB9ATSHRAGXTIDO1 | |
| Hydrochloric Acid SCHEMBL11220071 | 0.80 | TSHR (0.55) | NPC1RAB9ATSHRAGXTIDO1 | |
| SCHEMBL538293 | 0.77 | TSHR (0.57) | NPC1RAB9ATSHRAGXTIDO1 | |
| Hydrochloric Acid SCHEMBL6477571 | 0.76 | MAPT (0.50) | NPC1RAB9ATSHRAGXTIDO1 | |
| Hydrochloric Acid SCHEMBL28989899 | 0.76 | NPC1 (0.67) | NPC1RAB9AAGXTALDH1A1SLC6A2 | |
| SCHEMBL23489775 | 0.76 | NPC1 (0.40) | NPC1RAB9ATSHRAGXTIDO1 | |
| Hydrochloric Acid SCHEMBL584919 | 0.74 | AGXT (0.48) | NPC1RAB9ATSHRAGXTIDO1 | |
| Hydrochloric Acid SCHEMBL6967279 | 0.74 | HRAS (0.62) | NPC1RAB9ATSHRAGXTIDO1 | |
| SCHEMBL6509893 | 0.74 | NPC1 (0.65) | NPC1RAB9AALDH1A1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116023323-B | Preparation method of avibactam intermediate | 浙江工业大学 | 2025-06-17 | — | — | CN | claimed |
| CN-116023323-A | Preparation method of avibactam intermediate | 浙江工业大学 | 2023-04-28 | — | — | CN | claimed |
| CN-116023323-B | Preparation method of avibactam intermediate | 浙江工业大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-117946025-A | 1-Oxygen-2, 8-diazacyclic sunflower ketone derivative and synthetic method and application thereof | 广西师范大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-116023323-A | Preparation method of avibactam intermediate | 浙江工业大学 | 2023-04-28 | — | — | CN | disclosed |
| CN-107033052-A | A kind of preparation method of actinonin | 华东师范大学 | 2017-08-11 | — | — | CN | disclosed |
| CN-107033052-A | A kind of preparation method of actinonin | 华东师范大学 | 2017-08-11 | — | — | CN | disclosed |
| EP-2806873-A1 | AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AiCuris GmbH & Co. KG (DE) | 2014-12-03 | — | — | EP | disclosed |
| US-8513246-B2 | Use of N-heterocyclylmethylbenzamides in therapeutics | SANOFI (FR) | 2013-08-20 | — | — | US | disclosed |
| WO-2013110643-A1 | AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AICURIS GMBH & CO. KG (DE) | 2013-08-01 | — | — | WO | disclosed |
| CN-101684118-B | Use of tricyclic compounds as glycine transport inhibitors | SANOFI AVENTIS | 2013-04-10 | — | — | CN | disclosed |
| EP-1706205-A1 | A CATALYTIC ASYMMETRIC EPOXIDATION | University of Chicago (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-0982026-B1 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | disclosed |
| CN-1223581-C | Method for synthesizing benzyloxy amine hydrochloride | UNIV XIAMEN (CN) | 2005-10-19 | — | — | CN | disclosed |
| WO-2005072868-A1 | A CATALYTIC ASYMMETRIC EPOXIDATION | UNIVERSITY OF CHICAGO (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050159607-A1 | Catalytic asymmetric epoxidation | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2005-07-21 | — | — | US | disclosed |
| CN-1141936-C | Usage of aryl-cyclohexylamine derivant in anti-disturbance of central nervous system | - | 2004-03-17 | — | — | CN | disclosed |
| US-6184236-B1 | Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative | HOFFMANN-LA ROCHE INC. | 2001-02-06 | — | — | US | disclosed |
| CN-1248439-A | Usage of aryl-cyclohexylamine derivant in anti-disturbance of central nervous system | HOFFMAN LA ROCHE & CO AKTEINGE (DE) | 2000-03-29 | — | — | CN | disclosed |
| EP-0982026-A2 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159607-A1 | Catalytic asymmetric epoxidation | DUOX1, DUOX2, EPHX2 | SLC6A2 4259/4885SLC6A3 4122/4885PTGS1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.